Compare VTR & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTR | TEVA |
|---|---|---|
| Founded | 1983 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3B | 30.2B |
| IPO Year | 1998 | N/A |
| Metric | VTR | TEVA |
|---|---|---|
| Price | $75.71 | $32.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 9 |
| Target Price | ★ $78.43 | $32.67 |
| AVG Volume (30 Days) | 3.1M | ★ 9.3M |
| Earning Date | 02-11-2026 | 01-28-2026 |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.53 | ★ 0.62 |
| Revenue | $5,544,046,000.00 | ★ $16,776,000,000.00 |
| Revenue This Year | $17.34 | $4.62 |
| Revenue Next Year | $10.07 | $0.34 |
| P/E Ratio | $144.33 | ★ $52.03 |
| Revenue Growth | ★ 16.38 | 0.02 |
| 52 Week Low | $56.68 | $12.47 |
| 52 Week High | $81.89 | $32.91 |
| Indicator | VTR | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 34.38 | 78.56 |
| Support Level | $74.95 | $30.47 |
| Resistance Level | $80.02 | $32.91 |
| Average True Range (ATR) | 1.08 | 0.59 |
| MACD | -0.53 | -0.14 |
| Stochastic Oscillator | 16.80 | 84.84 |
Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.